Pharmacovigilance – Products

This application note outlines the importance of reagent consistency in organoid tissue culture.

Revvity, Inc announced the launch of its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.

RemeGen Co., Ltd announced the latest clinical research results on disitamab vedotin at this year's American Society of Clinical Oncology Annual Meeting.

Samsara Therapeutics has announced the company’s autophagy-inducing candidate SAM001, the first agent of its class to enter clinical trials.

Gyros Protein Technologies AB has announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

An analysis of NHS prescriptions data has revealed the huge potential for pharmacogenomics to reduce ineffective prescribing and adverse effects, which could save millions of pounds for the NHS.

CARNK cell therapies are novel therapeutic options developed with the aim to overcome some limitations of CART cell therapies, such as therapy induced side effects.

Avacta Group plc announces the opening of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.

EpicentRx, Inc. has announced that the FDA has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.

Protein-targeting chimeras (PROTACs) have gained significant attention recently due to their high potency in nanomolar drug concentrations and target selectivity. However, low test concentrations in complex matrices present analytical challenges.